心肌梗死后左室重构的心脏磁共振评估:预后、监测与试验终点
本综述概述心肌梗死后不良左室重构(ALVR)及后续心力衰竭,指出炎症是心肌纤维化和ALVR的共同通路。心脏磁共振(CMR)可同时提供心脏结构、功能、灌注和组织特征信息,有助于预后判断和指导高危人群的早期监测与治疗。已确立和正在发展的CMR衍生生物标志物可能作为评估新型抗炎和抗纤维化治疗的前瞻性试验的临床终点。
要点
- CMR可同时评估心脏结构、功能、灌注和组织特征,用于心肌梗死后不良左室重构的预后判断。
- CMR衍生生物标志物可能作为抗炎和抗纤维化治疗试验的临床终点。
- 炎症是心肌梗死后心肌纤维化和不良左室重构的共同通路。
核心结论
- CMR通过机制性或预后性影像标志物,可能有助于新型疗法在临床中的采用。
研究设计与样本
- 综述,检索范围与纳入文献数原文未报告。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Adverse left ventricular remodeling (ALVR) and subsequent heart failure after myocardial infarction (MI) remain a major cause of patient morbidity and mortality worldwide. Overt inflammation has been identified as the common pathway underlying myocardial fibrosis and development of ALVR post-MI. With its ability to simultaneously provide information about cardiac structure, function, perfusion, and tissue characteristics, cardiac magnetic resonance (CMR) is well poised to inform prognosis and guide early surveillance and therapeutics in high-risk cohorts. Further, established and evolving CMR-derived biomarkers may serve as clinical endpoints in prospective trials evaluating the efficacy of novel anti-inflammatory and antifibrotic therapies. This review provides an overview of post-MI ALVR and illustrates how CMR may help clinical adoption of novel therapies via mechanistic or prognostic imaging markers.
引用
- Gissler MC, Antiochos P, Ge Y, et al. Cardiac Magnetic Resonance Evaluation of LV Remodeling Post-Myocardial Infarction: Prognosis, Monitoring and Trial Endpoints. JACC Cardiovasc Imaging. 2024. PMID: 38819335. doi:10.1016/j.jcmg.2024.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。